Prevention of febrile leucopenia after chemotherapy in high-risk breast cancer patients : no significant difference between granulocyte-colony stimulating growth factor or ciprofloxacin plus amphotericin B
In a prospective randomized trial, 40 stage IV breast cancer patients undergoing intermediate high-dose chemotherapy (cyclophosphamide, 5-fluorouracil plus epirubicin or methotrexate), received either recombinant human G-CSF (rhG-CSF, group I) or ciprofloxacin and amphotericin B (CAB, group II) for...
Gespeichert in:
| Veröffentlicht in: | Journal of antimicrobial chemotherapy 1999-05, Vol.43 (5), p.741-743 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 743 |
|---|---|
| container_issue | 5 |
| container_start_page | 741 |
| container_title | Journal of antimicrobial chemotherapy |
| container_volume | 43 |
| creator | SCHRÖDER, C. P DE VRIES, E. G. E MULDER, N. H WILLEMSE, P. H. B SLEIJFER, D. T HOSPERS, G. A. P VAN DER GRAAF, W. T. A |
| description | In a prospective randomized trial, 40 stage IV breast cancer patients undergoing intermediate high-dose chemotherapy (cyclophosphamide, 5-fluorouracil plus epirubicin or methotrexate), received either recombinant human G-CSF (rhG-CSF, group I) or ciprofloxacin and amphotericin B (CAB, group II) for prevention of febrile leucopenia (FL). In group I, seven of 18 patients developed FL (after 10/108 courses); in group II, seven of 22 patients (7/98 courses) (P = NS). Median hospitalization duration and costs were not different. RhG-CSF was 6.6 times more expensive per course than CAB. In conclusion, prophylactic CAB has similar efficacy to rhG-CSF in this setting, and is more cost-effective. |
| doi_str_mv | 10.1093/jac/43.5.741 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_217669531</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>376637951</sourcerecordid><originalsourceid>FETCH-LOGICAL-c381t-aecd9a7a2e920b77a9cd5755f95ba4e7fac6b8d196445ea961b14f6b1ede7d43</originalsourceid><addsrcrecordid>eNpNkU-LFDEQxYMo7uzqzbME8WjPJp2ku-NNF__Bgh723lSnK9MZe5I2Se86H9LvZJYZUCgoqPrx6lGPkFecbTnT4noP5lqKrdq2kj8hGy4bVtVM86dkwwRTVSuVuCCXKe0ZY41quufkgjPR1ZrVG_LnR8R79NkFT4OlFofoZqQzriYs6B1QsBkjNRMeQp4wwnKkztPJ7aYquvSTDhEhZWrAm8ItkF2RS_Q99YEmt_POurLLdHTWYsRC0QHzA6Knuwh-nYM5ZqxMmIM_0pTdYZ2LiN-VdXjIE7Vgcoi0lHFLDHYOv8EUC8u8JgqHZQrFoHucfHxBnlmYE7489yty9_nT3c3X6vb7l283H24rIzqeK0AzamihRl2zoW1Bm1G1SlmtBpDYlovN0I1cN1IqBN3wgUvbDBxHbEcprsibk2yx82vFlPt9WKMvF_uat02jleAFeneCTAwpRbT9Et0B4rHnrH9Mri_J9VL0qi_JFfz1WXMdDjj-B5-iKsDbMwDJwGzL74xL_7iOCd114i9Lu6hg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>217669531</pqid></control><display><type>article</type><title>Prevention of febrile leucopenia after chemotherapy in high-risk breast cancer patients : no significant difference between granulocyte-colony stimulating growth factor or ciprofloxacin plus amphotericin B</title><source>Oxford University Press Journals All Titles (1996-Current)</source><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Free Full-Text Journals in Chemistry</source><creator>SCHRÖDER, C. P ; DE VRIES, E. G. E ; MULDER, N. H ; WILLEMSE, P. H. B ; SLEIJFER, D. T ; HOSPERS, G. A. P ; VAN DER GRAAF, W. T. A</creator><creatorcontrib>SCHRÖDER, C. P ; DE VRIES, E. G. E ; MULDER, N. H ; WILLEMSE, P. H. B ; SLEIJFER, D. T ; HOSPERS, G. A. P ; VAN DER GRAAF, W. T. A</creatorcontrib><description>In a prospective randomized trial, 40 stage IV breast cancer patients undergoing intermediate high-dose chemotherapy (cyclophosphamide, 5-fluorouracil plus epirubicin or methotrexate), received either recombinant human G-CSF (rhG-CSF, group I) or ciprofloxacin and amphotericin B (CAB, group II) for prevention of febrile leucopenia (FL). In group I, seven of 18 patients developed FL (after 10/108 courses); in group II, seven of 22 patients (7/98 courses) (P = NS). Median hospitalization duration and costs were not different. RhG-CSF was 6.6 times more expensive per course than CAB. In conclusion, prophylactic CAB has similar efficacy to rhG-CSF in this setting, and is more cost-effective.</description><identifier>ISSN: 0305-7453</identifier><identifier>ISSN: 1460-2091</identifier><identifier>EISSN: 1460-2091</identifier><identifier>DOI: 10.1093/jac/43.5.741</identifier><identifier>PMID: 10382902</identifier><identifier>CODEN: JACHDX</identifier><language>eng</language><publisher>Oxford: Oxford University Press</publisher><subject><![CDATA[Adult ; Amphotericin B - economics ; Amphotericin B - therapeutic use ; Antineoplastic Combined Chemotherapy Protocols - adverse effects ; Biological and medical sciences ; Breast Neoplasms - drug therapy ; Ciprofloxacin - economics ; Ciprofloxacin - therapeutic use ; Costs and Cost Analysis ; Cyclophosphamide - administration & dosage ; Drug Therapy, Combination ; Drug toxicity and drugs side effects treatment ; Epirubicin - administration & dosage ; Female ; Fever - complications ; Fever - prevention & control ; Fluorouracil - administration & dosage ; Granulocyte Colony-Stimulating Factor - economics ; Granulocyte Colony-Stimulating Factor - therapeutic use ; Humans ; Length of Stay - economics ; Leukopenia - chemically induced ; Leukopenia - prevention & control ; Medical sciences ; Methotrexate - administration & dosage ; Middle Aged ; Neoplasm Metastasis ; Netherlands ; Pharmacology. Drug treatments ; Prospective Studies ; Recombinant Proteins - economics ; Recombinant Proteins - therapeutic use ; Toxicity: blood]]></subject><ispartof>Journal of antimicrobial chemotherapy, 1999-05, Vol.43 (5), p.741-743</ispartof><rights>1999 INIST-CNRS</rights><rights>Copyright Oxford University Press(England) May 1999</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c381t-aecd9a7a2e920b77a9cd5755f95ba4e7fac6b8d196445ea961b14f6b1ede7d43</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1803988$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10382902$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>SCHRÖDER, C. P</creatorcontrib><creatorcontrib>DE VRIES, E. G. E</creatorcontrib><creatorcontrib>MULDER, N. H</creatorcontrib><creatorcontrib>WILLEMSE, P. H. B</creatorcontrib><creatorcontrib>SLEIJFER, D. T</creatorcontrib><creatorcontrib>HOSPERS, G. A. P</creatorcontrib><creatorcontrib>VAN DER GRAAF, W. T. A</creatorcontrib><title>Prevention of febrile leucopenia after chemotherapy in high-risk breast cancer patients : no significant difference between granulocyte-colony stimulating growth factor or ciprofloxacin plus amphotericin B</title><title>Journal of antimicrobial chemotherapy</title><addtitle>J Antimicrob Chemother</addtitle><description>In a prospective randomized trial, 40 stage IV breast cancer patients undergoing intermediate high-dose chemotherapy (cyclophosphamide, 5-fluorouracil plus epirubicin or methotrexate), received either recombinant human G-CSF (rhG-CSF, group I) or ciprofloxacin and amphotericin B (CAB, group II) for prevention of febrile leucopenia (FL). In group I, seven of 18 patients developed FL (after 10/108 courses); in group II, seven of 22 patients (7/98 courses) (P = NS). Median hospitalization duration and costs were not different. RhG-CSF was 6.6 times more expensive per course than CAB. In conclusion, prophylactic CAB has similar efficacy to rhG-CSF in this setting, and is more cost-effective.</description><subject>Adult</subject><subject>Amphotericin B - economics</subject><subject>Amphotericin B - therapeutic use</subject><subject>Antineoplastic Combined Chemotherapy Protocols - adverse effects</subject><subject>Biological and medical sciences</subject><subject>Breast Neoplasms - drug therapy</subject><subject>Ciprofloxacin - economics</subject><subject>Ciprofloxacin - therapeutic use</subject><subject>Costs and Cost Analysis</subject><subject>Cyclophosphamide - administration & dosage</subject><subject>Drug Therapy, Combination</subject><subject>Drug toxicity and drugs side effects treatment</subject><subject>Epirubicin - administration & dosage</subject><subject>Female</subject><subject>Fever - complications</subject><subject>Fever - prevention & control</subject><subject>Fluorouracil - administration & dosage</subject><subject>Granulocyte Colony-Stimulating Factor - economics</subject><subject>Granulocyte Colony-Stimulating Factor - therapeutic use</subject><subject>Humans</subject><subject>Length of Stay - economics</subject><subject>Leukopenia - chemically induced</subject><subject>Leukopenia - prevention & control</subject><subject>Medical sciences</subject><subject>Methotrexate - administration & dosage</subject><subject>Middle Aged</subject><subject>Neoplasm Metastasis</subject><subject>Netherlands</subject><subject>Pharmacology. Drug treatments</subject><subject>Prospective Studies</subject><subject>Recombinant Proteins - economics</subject><subject>Recombinant Proteins - therapeutic use</subject><subject>Toxicity: blood</subject><issn>0305-7453</issn><issn>1460-2091</issn><issn>1460-2091</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1999</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpNkU-LFDEQxYMo7uzqzbME8WjPJp2ku-NNF__Bgh723lSnK9MZe5I2Se86H9LvZJYZUCgoqPrx6lGPkFecbTnT4noP5lqKrdq2kj8hGy4bVtVM86dkwwRTVSuVuCCXKe0ZY41quufkgjPR1ZrVG_LnR8R79NkFT4OlFofoZqQzriYs6B1QsBkjNRMeQp4wwnKkztPJ7aYquvSTDhEhZWrAm8ItkF2RS_Q99YEmt_POurLLdHTWYsRC0QHzA6Knuwh-nYM5ZqxMmIM_0pTdYZ2LiN-VdXjIE7Vgcoi0lHFLDHYOv8EUC8u8JgqHZQrFoHucfHxBnlmYE7489yty9_nT3c3X6vb7l283H24rIzqeK0AzamihRl2zoW1Bm1G1SlmtBpDYlovN0I1cN1IqBN3wgUvbDBxHbEcprsibk2yx82vFlPt9WKMvF_uat02jleAFeneCTAwpRbT9Et0B4rHnrH9Mri_J9VL0qi_JFfz1WXMdDjj-B5-iKsDbMwDJwGzL74xL_7iOCd114i9Lu6hg</recordid><startdate>19990501</startdate><enddate>19990501</enddate><creator>SCHRÖDER, C. P</creator><creator>DE VRIES, E. G. E</creator><creator>MULDER, N. H</creator><creator>WILLEMSE, P. H. B</creator><creator>SLEIJFER, D. T</creator><creator>HOSPERS, G. A. P</creator><creator>VAN DER GRAAF, W. T. A</creator><general>Oxford University Press</general><general>Oxford Publishing Limited (England)</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7QO</scope><scope>7T7</scope><scope>7U7</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>NAPCQ</scope><scope>P64</scope></search><sort><creationdate>19990501</creationdate><title>Prevention of febrile leucopenia after chemotherapy in high-risk breast cancer patients : no significant difference between granulocyte-colony stimulating growth factor or ciprofloxacin plus amphotericin B</title><author>SCHRÖDER, C. P ; DE VRIES, E. G. E ; MULDER, N. H ; WILLEMSE, P. H. B ; SLEIJFER, D. T ; HOSPERS, G. A. P ; VAN DER GRAAF, W. T. A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c381t-aecd9a7a2e920b77a9cd5755f95ba4e7fac6b8d196445ea961b14f6b1ede7d43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1999</creationdate><topic>Adult</topic><topic>Amphotericin B - economics</topic><topic>Amphotericin B - therapeutic use</topic><topic>Antineoplastic Combined Chemotherapy Protocols - adverse effects</topic><topic>Biological and medical sciences</topic><topic>Breast Neoplasms - drug therapy</topic><topic>Ciprofloxacin - economics</topic><topic>Ciprofloxacin - therapeutic use</topic><topic>Costs and Cost Analysis</topic><topic>Cyclophosphamide - administration & dosage</topic><topic>Drug Therapy, Combination</topic><topic>Drug toxicity and drugs side effects treatment</topic><topic>Epirubicin - administration & dosage</topic><topic>Female</topic><topic>Fever - complications</topic><topic>Fever - prevention & control</topic><topic>Fluorouracil - administration & dosage</topic><topic>Granulocyte Colony-Stimulating Factor - economics</topic><topic>Granulocyte Colony-Stimulating Factor - therapeutic use</topic><topic>Humans</topic><topic>Length of Stay - economics</topic><topic>Leukopenia - chemically induced</topic><topic>Leukopenia - prevention & control</topic><topic>Medical sciences</topic><topic>Methotrexate - administration & dosage</topic><topic>Middle Aged</topic><topic>Neoplasm Metastasis</topic><topic>Netherlands</topic><topic>Pharmacology. Drug treatments</topic><topic>Prospective Studies</topic><topic>Recombinant Proteins - economics</topic><topic>Recombinant Proteins - therapeutic use</topic><topic>Toxicity: blood</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>SCHRÖDER, C. P</creatorcontrib><creatorcontrib>DE VRIES, E. G. E</creatorcontrib><creatorcontrib>MULDER, N. H</creatorcontrib><creatorcontrib>WILLEMSE, P. H. B</creatorcontrib><creatorcontrib>SLEIJFER, D. T</creatorcontrib><creatorcontrib>HOSPERS, G. A. P</creatorcontrib><creatorcontrib>VAN DER GRAAF, W. T. A</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><jtitle>Journal of antimicrobial chemotherapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>SCHRÖDER, C. P</au><au>DE VRIES, E. G. E</au><au>MULDER, N. H</au><au>WILLEMSE, P. H. B</au><au>SLEIJFER, D. T</au><au>HOSPERS, G. A. P</au><au>VAN DER GRAAF, W. T. A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prevention of febrile leucopenia after chemotherapy in high-risk breast cancer patients : no significant difference between granulocyte-colony stimulating growth factor or ciprofloxacin plus amphotericin B</atitle><jtitle>Journal of antimicrobial chemotherapy</jtitle><addtitle>J Antimicrob Chemother</addtitle><date>1999-05-01</date><risdate>1999</risdate><volume>43</volume><issue>5</issue><spage>741</spage><epage>743</epage><pages>741-743</pages><issn>0305-7453</issn><issn>1460-2091</issn><eissn>1460-2091</eissn><coden>JACHDX</coden><abstract>In a prospective randomized trial, 40 stage IV breast cancer patients undergoing intermediate high-dose chemotherapy (cyclophosphamide, 5-fluorouracil plus epirubicin or methotrexate), received either recombinant human G-CSF (rhG-CSF, group I) or ciprofloxacin and amphotericin B (CAB, group II) for prevention of febrile leucopenia (FL). In group I, seven of 18 patients developed FL (after 10/108 courses); in group II, seven of 22 patients (7/98 courses) (P = NS). Median hospitalization duration and costs were not different. RhG-CSF was 6.6 times more expensive per course than CAB. In conclusion, prophylactic CAB has similar efficacy to rhG-CSF in this setting, and is more cost-effective.</abstract><cop>Oxford</cop><pub>Oxford University Press</pub><pmid>10382902</pmid><doi>10.1093/jac/43.5.741</doi><tpages>3</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0305-7453 |
| ispartof | Journal of antimicrobial chemotherapy, 1999-05, Vol.43 (5), p.741-743 |
| issn | 0305-7453 1460-2091 1460-2091 |
| language | eng |
| recordid | cdi_proquest_journals_217669531 |
| source | Oxford University Press Journals All Titles (1996-Current); MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Free Full-Text Journals in Chemistry |
| subjects | Adult Amphotericin B - economics Amphotericin B - therapeutic use Antineoplastic Combined Chemotherapy Protocols - adverse effects Biological and medical sciences Breast Neoplasms - drug therapy Ciprofloxacin - economics Ciprofloxacin - therapeutic use Costs and Cost Analysis Cyclophosphamide - administration & dosage Drug Therapy, Combination Drug toxicity and drugs side effects treatment Epirubicin - administration & dosage Female Fever - complications Fever - prevention & control Fluorouracil - administration & dosage Granulocyte Colony-Stimulating Factor - economics Granulocyte Colony-Stimulating Factor - therapeutic use Humans Length of Stay - economics Leukopenia - chemically induced Leukopenia - prevention & control Medical sciences Methotrexate - administration & dosage Middle Aged Neoplasm Metastasis Netherlands Pharmacology. Drug treatments Prospective Studies Recombinant Proteins - economics Recombinant Proteins - therapeutic use Toxicity: blood |
| title | Prevention of febrile leucopenia after chemotherapy in high-risk breast cancer patients : no significant difference between granulocyte-colony stimulating growth factor or ciprofloxacin plus amphotericin B |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-11T08%3A49%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prevention%20of%20febrile%20leucopenia%20after%20chemotherapy%20in%20high-risk%20breast%20cancer%20patients%20:%20no%20significant%20difference%20between%20granulocyte-colony%20stimulating%20growth%20factor%20or%20ciprofloxacin%20plus%20amphotericin%20B&rft.jtitle=Journal%20of%20antimicrobial%20chemotherapy&rft.au=SCHR%C3%96DER,%20C.%20P&rft.date=1999-05-01&rft.volume=43&rft.issue=5&rft.spage=741&rft.epage=743&rft.pages=741-743&rft.issn=0305-7453&rft.eissn=1460-2091&rft.coden=JACHDX&rft_id=info:doi/10.1093/jac/43.5.741&rft_dat=%3Cproquest_cross%3E376637951%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=217669531&rft_id=info:pmid/10382902&rfr_iscdi=true |